Table 2.
Clinical Trials Influenced the Standard Treatment.
| Study name (year) | Histologic subtype* | Treatment arms** | Main results*** | |
|---|---|---|---|---|
| JCOG9204 (2003) | SCC | Surgery alone | 5y-DFS 45% | P = 0.037 |
| Surgery + CF | 5y-DFS 55% | |||
| MAGIC (2006) | Esophagogastric AC | Surgery alone | 5y-OS 23% | P = 0.009 |
| ECF + Surgery + ECF | 5y-OS 36% | |||
| JCOG9907 (2012) | SCC | Surgery + CF | 5y-OS 43% | P = 0.04 |
| CF + Surgery | 5y-OS 55% | |||
| CROSS (2012) | SCC, AC | Surgery alone | Median OS 24.0M | P = 0.003 |
| CRT + Surgery | Median OS 49.4M | |||
| FLOT (2017) | Esophagogastric AC | ECF or ECX + Surgery + ECF or ECX | Median OS 35M | P = 0.012 |
| FLOT + Surgery + FLOT | Median OS 50M | |||
*SCC, squamous cell carcinoma; AC, adenocarcinoma.
**CF, cisplatin+5-fluorouracil; ECF, epirubicine+cisplatin+5-fluorouracil; ECX, epirubicine+cisplatin+xeloda; CRT, chemoradiotherapy; FLOT, 5-fluorouracil/leucovolin+oxaliplatin+taxotere
***DFS, disease-free survival; OS, overall survival.